MARKET

SVRA

SVRA

Savara Inc
NASDAQ
5.15
-0.12
-2.28%
Opening 13:23 05/15 EDT
OPEN
5.15
PREV CLOSE
5.27
HIGH
5.29
LOW
5.04
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
7.01
52 WEEK LOW
1.890
MARKET CAP
1.06B
P/E (TTM)
-9.2244
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Encompass Health (EHC) and SI-Bone (SIBN)
TipRanks · 2d ago
Savara (SVRA) Receives a Buy from Piper Sandler
TipRanks · 2d ago
Guggenheim Reaffirms Their Buy Rating on Savara (SVRA)
TipRanks · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: Kura Oncology (KURA), Savara (SVRA)
TipRanks · 2d ago
Savara reports Q1 EPS (15c), consensus (14c)
TipRanks · 3d ago
Savara Q1 EPS $(0.15) Misses $(0.14) Estimate
Benzinga · 3d ago
Savara posts corporate presentation on autoimmune PAP, highlights MOLBREEVI Phase 3 data
PUBT · 3d ago
Savara GAAP EPS of -$0.15 misses by $0.01
Seeking Alpha · 3d ago
More
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Webull offers Savara Inc stock information, including NASDAQ: SVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SVRA stock methods without spending real money on the virtual paper trading platform.